By Anthony O. Goriainoff

AstraZeneca PLC said on Monday that results from its TOPAZ-1 Phase 3 trial on its human monoclonal antibody, Imfinzi, showed it significantly improved overall survival in advanced biliary tract cancer patients.

The London-listed pharmaceutical company said Imfinzi, in combination with standard-of-care chemotherapy, showed a "statistically significant and clinically meaningful" overall survival when compared with chemotherapy alone.

"We believe the significant survival benefit demonstrated marks a new era of immunotherapy treatment in this devastating disease, and it advances our commitment to improving long-term survival for patients across these cancers where treatment options are limited," the company said.

Write to Anthony O. Goriainoff at anthony.orunagoriainoff@dowjones.com

(END) Dow Jones Newswires

October 25, 2021 02:31 ET (06:31 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Astrazeneca Charts.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Astrazeneca Charts.